Class Law Suit against UNS, page-4

Biodel: Settlement in tangible Unilife Suit!
sharedeals.de, 29/08/16
In since last year simmering dispute with the Unilife Corporation (WKN: A2AJXU ) carves for our biotech Tip of the year Biodel(WKN: A1JZU5) a last hardly expected windfall to. This is indicated by a new court document from last Friday through.

Unilife has the competent court requested a postponement of all court specified deadlines by 30 days and can also hinted that an agreement is imminent with Biodel.Specifically located one in advanced discussions regarding a Settlements and another intervention of a court may be seen as no longer required to. This step could Unilifes for Biodel not only mean an immediate ringing at the box office as well as the liberation of contaminated sites before the pending merger with Albireo, but also make it the remaining for sale clinical diabetes assets may be easier monetary terms.


Unilife was in 2013 an exclusive worldwide deal with Biodel received, thereby Biodel were granted the right to use the glucagon-house developed with Unilifes EZmix-syringe and market as its own product. Due to internal failings and shortcomings but Unilife could not meet as planned, as a result, among other things, management's part of the agreement took his hat .

The commercialization of Biodels planned Glucagon Emergency Management Kits marched into the distance, and many millions of development funds were apparently nothing overdone. Just a few months before Biodel 2015 lawsuit against Unilife filed, 30 million dollars were raised in investor funds for further development and commercialization of glucagon product.Hopes were investors mutually correspondingly large.

Bonus cash advance
The fact that Unilife would now in turn have the action quickly from the table, in our view, is related to the end of July were made renewal of leadership within the company.Kolportierte compensation sums in the tens of millions clearly we do not expect as part of the Settlements. Realistically, an amount 500000-5 million dollars seems. Even so could Biodel shareholders live excellently, since all now realized cash inflows known represent only some extra money on the already very advantageous merger with Ablireo and are not priced into the current market capitalization.

After the tremendously positive intermediate results of Albireos ongoing A4250 study and the recent announcement Unilifes to agree likely to short out of court, the sign of Biodel shareholders are getting better and the first of numerous known price catalysts back within reach.

Conflict of interest The author of this publication at the time of publication holds shares of the company discussed here Biodel and intends this - even at short notice - to sell and could in particular benefit from increased trading liquidity.This is specifically and clearly a conflict of interest. Please note our full disclosure and additional information according to Section 34b para 1 WpHG in conjunction with Trading Act (Germany):.Sharedeals.de/haftungsausschluss .


Source: sharedeals.de


0" style="box-sizing: border-box; margin-bottom: 5px; width: 360px;">
Top News

Tesla Motors: There is no middle seems to be
Nicolai_Tietze, 26/08/16

German Bank: shunned by investors
Robert_Sasse, 29/08/16
Request analysis ThyssenKrupp
Heibel-Ticker, 29/08/16

Barrick Gold: turnaround in the mine operators?
Robert_Sasse, 29/08/16



HOME
Sharewise Now!
DASHBOARD
Log In
My Watch ListsMy depotsMy assessments
MARKETS
overview
COMMUNITY
OverviewassessmentsForumRumors
NEWS
All News
ACCOUNT
Loginto Web version
ABOUT
Privacy PolicyTerms and ConditionsDisclaimerImprint





show